Omeros EPS Beats Estimates, Stock Rises 6.4%
Omeros reported a second-quarter EPS of $0.10 against a consensus loss, driving a 6.4% share price increase.
Omeros shares closed at $18.45 on September 17, 2026, marking a 6.40% increase from the previous session. The stock price movement coincides with the release of second-quarter 2026 financial results, which showed a significant deviation from analyst expectations. The company reported diluted earnings per share of $0.10, a figure that contrasts sharply with the consensus estimate of a $0.33 loss. This positive surprise of $0.43 per share signals a reversal in profitability trends for the period ending June 30, 2026.
The earnings beat follows a strong first quarter where Omeros recorded $0.57 in EPS against an expected loss of $0.39. Over the trailing twelve months, the company generated $38.42 million in revenue and $116.53 million in net income attributable to common shareholders. These figures result in a trailing diluted EPS of $1.65 and a profit margin of 324.88%. While small-cap biotech margins can be volatile due to one-off items, the consecutive quarters of positive earnings provide a stable baseline for valuation assessments.
Quarterly Performance Exceeds Consensus Forecasts
Data compiled by GN stocks/earnings-beat highlights a consistent pattern of upside surprises in recent reporting periods. In the quarter ending September 30, 2025, Omeros posted an EPS of -$0.32, which was still $0.16 higher than the forecast loss of $0.48. The subsequent quarter ending December 31, 2025, saw a more substantial beat with EPS of $3.14 compared to a consensus of $2.24. The most recent two quarters have solidified this trend, with the company delivering positive earnings where analysts generally projected losses.
This divergence between actual results and expectations has altered the risk-reward calculation for investors. The shift from expected losses to actual positive EPS in Q1 and Q2 2026 indicates that operational costs and revenue generation are aligning more favorably than previously modeled. The trailing twelve-month profit margin of over 300% underscores the magnitude of this improvement, although it may reflect specific accounting adjustments or one-time gains typical in the sector.
Forward Estimates Indicate Revenue Growth
Looking ahead, analyst consensus projects a slight dip in earnings for the current quarter ending September 30, 2026, with an estimated EPS of -$0.03. However, expectations turn positive for the quarter ending December 31, 2026, with projected EPS of $0.05. Full-year 2026 estimates point to EPS of $0.66, rising to $1.14 in 2027. These figures suggest that while short-term volatility persists, the long-term trajectory remains upward.
Revenue projections show a steady increase, with estimates of $36.7 million for the current quarter and $50.5 million for the next. Full-year 2026 revenue is expected to reach $125.6 million, expanding to $197.8 million in 2027. This top-line growth is expected to support the gradual strengthening of earnings power. The consensus view among two to three analysts reflects a cautious but optimistic stance on the company's ability to convert revenue growth into sustainable profitability.
Valuation Metrics Reflect Mixed Multiples
As of September 17, 2026, Omeros trades at a trailing price-to-earnings ratio of 10.50, based on the recent share price and diluted EPS of $1.65. In contrast, the forward P/E ratio stands at 71.94, reflecting near-term consensus figures that include a projected loss for the current quarter. This disparity between trailing and forward multiples indicates that the current valuation is heavily influenced by recent strong performance, while future expectations remain more conservative.
Analyst ratings remain predominantly bullish, with an average score of 2.67 on a scale where lower numbers indicate stronger conviction. The breakdown includes one strong buy, two buy, and three hold recommendations, with no sell ratings. The consensus price target of $38.00 implies potential upside from the recent reference price of approximately $18.48. This target price suggests that covering analysts expect further appreciation if the company can sustain its recent earnings momentum and meet revenue growth targets.
